We investigated whether sponsor-imposed publication restrictions for ClinicalTrials.gov trials were reasonable, based on consistency with Good Publication Practice 2 (GPP2). ClinicalTrials.gov trial record data were electronically imported (October 7, 2012) and screened for eligibility (phase 2–4, interventional, recruitment closed, results available, first received for registration after November 10, 2009, any sponsor type, investigators not sponsor employees). Two authors categorized restrictions information as consistent or not consistent with GPP2, resolving discrepancies by consensus. Of the eligible trials (388/484, n = 81,768 participants), 80.7% (313/388) had restrictions disclosed, and 92.5% (311/388) were industry-sponsored. Significantly more trials had restrictions that were consistent with GPP2 than not (74.1% [232/313], n = 55,280 participants vs. 25.9% [81/313], n = 19,677 participants; P
CITATION STYLE
Stretton, S., Lew, R. A., Ely, J. A., Snape, M. J., Carey, L. C., Haley, C., … Woolley, K. L. (2016). Sponsor-Imposed Publication Restrictions Disclosed on ClinicalTrials.gov. Accountability in Research, 23(2), 67–78. https://doi.org/10.1080/08989621.2015.1020375
Mendeley helps you to discover research relevant for your work.